ArticlePloS one2015
Comparison of Depletion Strategies for the Enrichment of Low-Abundance Proteins in Urine.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Early Detection of Acute Kidney Injury After Congenital Heart Surgery-Using Urine Proteomics to Identify New Biomarker Candidates: A Prospective Clinical Study.Journal of clinical medicine · 2025Article
- Boosting Quantification of N-Glycans by an Enhanced Isobaric Multiplex Reagents for Carbonyl-Containing Compound (SUGAR) Tagging Strategy.Journal of the American Society for Mass Spectrometry · 2025Article
- Challenges and Opportunities in Quantifying Bioactive Compounds in Human Breastmilk.Biomolecules · 2025Review
- Urinary Proteomic Shifts over Time and Their Associations with eGFR Decline in Chronic Kidney Disease.Biomolecules · 2025Article
- Candidate protein biomarkers in chronic kidney disease: a proteomics study.Scientific reports · 2024Article
- Differences in the Synovial Fluid Proteome of Septic and Aseptic Implant Failure.Antibiotics (Basel, Switzerland) · 2024Article
- Recent developments in mass-spectrometry-based targeted proteomics of clinical cancer biomarkers.Clinical proteomics · 2024Review
- Quantitative analysis of therapeutic proteins in biological fluids: recent advancement in analytical techniques.Drug delivery · 2023Review
- Proteomics evaluation of five economical commercial abundant protein depletion kits for enrichment of diseases-specific biomarkers from blood serum.Proteomics · 2023Article
- Quantitative Mass Spectrometry Normalization in Urine Biomarker Analysis in Nephrotic Syndrome.Glomerular diseases · 2022Article
- Review of Liquid Chromatography-Mass Spectrometry-Based Proteomic Analyses of Body Fluids to Diagnose Infectious Diseases.International journal of molecular sciences · 2022Review
- Molecular profiling of urinary extracellular vesicles in chronic kidney disease and renal fibrosis.Frontiers in pharmacology · 2022Review
- Clinical Proteomics of Biofluids in Haematological Malignancies.International journal of molecular sciences · 2021Review
- Functional secretome analysis reveals Annexin-A1 as important paracrine factor derived from fetal mesenchymal stem cells in hepatic regeneration.EBioMedicine · 2019Article
- Highly Efficient Phosphoproteome Capture and Analysis from Urinary Extracellular Vesicles.Journal of proteome research · 2018Article
- Review
- Article
- Current state of the art for enhancing urine biomarker discovery.Expert review of proteomics · 2016Review
- Biomarker discovery in mass spectrometry-based urinary proteomics.Proteomics. Clinical applications · 2016Review
- Human Urine Proteomics: Analytical Techniques and Clinical Applications in Renal Diseases.International journal of proteomics · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proteome analysis of complex biological samples for biomarker identification remains challenging, among others due to the extended range of protein concentrations. High-abundance proteins like albumin or IgG of plasma and urine, may interfere with the detection of potential disease biomarkers. Currently, several options are available for the depletion of abundant proteins in plasma. However, the applicability of these methods in urine has not been thoroughly investigated. In this study, we compared different, commercially available immunodepletion and ion-exchange based approaches on urine samples from both healthy subjects and CKD patients, for their reproducibility and efficiency in protein depletion. A starting urine volume of 500 μL was used to simulate conditions of a multi-institutional biomarker discovery study. All depletion approaches showed satisfactory reproducibility (n=5) in protein identification as well as protein abundance. Comparison of the depletion efficiency between the unfractionated and fractionated samples and the different depletion strategies, showed efficient depletion in all cases, with the exception of the ion-exchange kit. The depletion efficiency was found slightly higher in normal than in CKD samples and normal samples yielded more protein identifications than CKD samples when using both initial as well as corresponding depleted fractions. Along these lines, decrease in the amount of albumin and other targets as applicable, following depletion, was observed. Nevertheless, these depletion strategies did not yield a higher number of identifications in neither the urine from normal nor CKD patients. Collectively, when analyzing urine in the context of CKD biomarker identification, no added value of depletion strategies can be observed and analysis of unfractionated starting urine appears to be preferable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.